marijuana stocks

Trulieve Reports Q1 Revenues of $96.1 Million, Net Income of $14.0 Million

 

Trulieve Cannabis (CSE: TRUL) reported its first-quarter 2020 financial results this morning, posting revenues of $96.1 million for the period ended March 31, 2020, while posting a net income of $14.0 million.

Revenues were a significant quarter over quarter improvement from the firms fourth quarter, rising 21% while gross margins were up 30%. Trulieve reported a gross margin of $67.1 million before fair value adjustments for the quarter. However, operating expenses grew by 21%, showing that they are relatively consistent when compared to that of revenues, with expenses coming in at $28.3 million, as compared to $23.4 million in the prior quarter.

Total expenses came in at $31.5 million, with the company pulling out depreciation and amortization from operating expenses. Sales and marketing was the largest expense at $22.0 million, followed by general and administrative at $6.3 million. After interest expenses of $6.9 million and other income of $4.9 million, the company reported a net income of $14.0 million after taxes.

Looking at the balance sheet, the firm saw an improvement in its cash position, reporting $100.8 million in the bank as compared to $91.8 million in the prior quarter. Inventories grew to $227.9 million from $204.45 million, while biological assets fell from $66.7 million to $41.3 million. Trulieve’s total current assets climbed to $384.5 million from $369.9 million over the three month period.

On the current liabilities side, the largest quarter over quarter increase was that of income tax payable, which grew from $12.2 million to $30.7 million. Accounts payable climbed to $25.9 million from $24.3 million. Total current liabilities overall grew from $56.7 million to $73.6 million.

Trulieve Cannabis last traded at $18.55 on the CSE.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Cresco Labs Inc. (CRLBF) Closes Acquisition of Pennsylvania Vertically Integrated Clinical Registrant

Cresco Labs Closes Acquisition of Pennsylvania Vertically Integrated Clinical Registrant, Laurel Harvest…

Cara Therapeutics, Inc. (CARA) to Announce Second Quarter 2023 Financial Results on August 7, 2023

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7,…

$GWPH Agreement to Study Epidiolex(R) and CBDV in a Clinical Trial

GW Pharmaceuticals and the Government of New South Wales Announce a Strategic…

$EDXC Begins Shipment of Third Eye Chai CBD-Infused Gourmet Tea Beverages

Endexx Begins Shipment of Third Eye Chai CBD-Infused Gourmet Tea Beverages Endexx…